



FIG. 1

<i>Tumor Type</i>	<i>Cell line</i>	<i>Response</i>	<i>Assay</i>
Melanoma	A375P	+++	a,b
	A375M	++	a
	Hs294T	+	a
	DX-3	NR	a
	SKMel-28	NR	a
	Mel-21	NR	a
	M-21	+	a
	AAB-1	++	a
	AAB-2	+	a
Breast	BT-20	NR	a
	MCF-7	+	a
	MCF-7/TNFR	++	a
	SKBr-3	+	a
Prostate	Du-145	NR	a
	PC-3	+	a
	LnCaP	+++	a,b
Ovarian	SKOV-3	NR	a
	NIH-OVCAR-3	NR	a
	HEY	++	a,b
Cervical	ME-180	NR	a
Vulvular	A431	NR	a
Non-small cell lung	H322	+	a,b
	H522	++	a,b
Colon	Ls174T	NR	a
Lymphoma	Raji	NR	b
	Jurkat	+	b
	U937	+++	b
Leukemia	K562	+++	b
	Molt-4	++	b
	HSB-2	NR	b
	THP-1	+	b
Normal Skin Fibroblasts	CRL-2103	NR	a


FIG. 2




0h



12h



4h



24h



8h




DMSO


F16.3




0 h



12 h



4 h



24 h




8 h




DMSO


FIG. 4



0h



4h





48h


~
DMSO

FIG-5



~
Extract





H 322



H 522



A 431



Ln CaP

FIG. 6




FIG. 7




FIG. 8(a)




FIG. 8(b)




FIG. 8

FIG. 9

Treatment	Route	# Animals	# With Tumor	% Tumor Positive
Control (PEG300-DMSO)	Intratumoral + Intraperitoneal	10	9	90 %
LP9 (1 mg)	Intratumoral + Intravenous	8	7	87.5 %
LP9 (1 mg)	Intratumoral + Intraperitoneal	9	3	33 %

FIG. 10

